Full-Time

Clinical Field Specialist

CT

Posted on 11/21/2024

HeartFlow

HeartFlow

501-1,000 employees

Non-invasive cardiac testing technology provider

Healthcare

Compensation Overview

$84.5k - $110kAnnually

+ Commission + Stock Options

Mid

Remote in USA

Remote position with up to 80% travel.

Category
Nursing & Allied Health Professionals
Medical, Clinical & Veterinary
Requirements
  • Expert knowledge of cardiac CT is required
  • Teaching and industry experience are highly desirable
  • Strong communication skills and demonstrated success in building relationships
  • Associate degree in radiology, technology or related field required; Bachelor’s Degree preferred
  • Minimum 3 years cardiac CTA experience
  • Must have active ARRT Certification in CT or Board Certified in Radiology
Responsibilities
  • Assess the customer lifecycle and ensure the coronary CT program is optimized to set up customers for success.
  • Identify areas of improvement and make recommendations to enhance quality acceptance rates during customer onboarding.
  • Ensure customer has implemented any necessary changes to optimize use of HeartFlow products on a continuous basis.
  • Conduct virtual and/or live training of technologists using various delivery methods, including product demonstrations, one-on-one, and group training sessions, to transfer knowledge on the use of HeartFlow products in assigned geography.
  • Establish credibility and sustain strong working relationships with key stakeholders.
  • Ensure proper records (e.g. customer contacts, CT volume, engagement logs, training records, etc.) and documentation are input and maintained in HeartFlow systems.
  • Capture customer feedback and participate in clinical discussions with customers and colleagues regarding HeartFlow analysis on multiple products.
  • Maintain knowledge of the latest CT and Workstation technology innovations, training delivery methodologies, and training materials for effective training.
  • Build and execute on plans to proactively optimize customer performance and identify opportunities for improvement.

HeartFlow provides a non-invasive cardiac test that helps visualize a patient's coronary arteries in detail. This technology allows physicians to diagnose and treat heart disease more effectively without the need for invasive procedures, which reduces risks for patients and costs for healthcare providers. HeartFlow's main clients are healthcare professionals seeking safer diagnostic methods. The company offers several analyses, including FFRCT Analysis and Plaque Analysis, which have received FDA clearance and are available in the U.S., U.K., Japan, and Canada. Unlike competitors, HeartFlow focuses on non-invasive solutions that enhance treatment planning. The goal is to improve cardiovascular care by making it safer and more efficient.

Company Stage

Series F

Total Funding

$858.5M

Headquarters

Redwood City, California

Founded

2010

Growth & Insights
Headcount

6 month growth

4%

1 year growth

16%

2 year growth

20%
Simplify Jobs

Simplify's Take

What believers are saying

  • The recent $215 million Series F funding round led by Bain Capital Life Sciences positions HeartFlow for significant growth and expansion.
  • HeartFlow's AI-enabled products, such as the RoadMap Analysis, enhance diagnostic accuracy and efficiency, potentially improving patient outcomes and physician workflows.
  • With coverage by 100% of Medicare and over 98% of commercial payers, HeartFlow's technology is widely accessible, increasing its adoption and market penetration.

What critics are saying

  • The cardiovascular care market is highly competitive, requiring continuous innovation to maintain a leading position.
  • Regulatory hurdles and the need for ongoing FDA clearances could delay product launches and market entry.

What makes HeartFlow unique

  • HeartFlow's non-invasive cardiac test offers a safer and more efficient alternative to traditional invasive procedures, setting it apart in the cardiovascular care market.
  • The company's comprehensive product portfolio, including FFRCT, RoadMap, and Plaque Analysis, provides a unique combination of anatomical and physiological visualization of coronary arteries.
  • HeartFlow's technology has received FDA clearance and is commercially available in multiple countries, ensuring a broad market reach and regulatory credibility.

Help us improve and share your feedback! Did you find this helpful?